Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
Oncotarget ; 6(31): 31344-59, 2015 Oct 13.
Article in English | MEDLINE | ID: mdl-26374823

ABSTRACT

Phenotypic heterogeneity of human carcinoma lesions, including heterogeneity in expression of tumor-associated antigens (TAAs), is a well-established phenomenon. Carcinoembryonic antigen (CEA), MUC1, and brachyury are diverse TAAs, each of which is expressed on a wide range of human tumors. We have previously reported on a novel adenovirus serotype 5 (Ad5) vector gene delivery platform (Ad5 [E1-, E2b-]) in which regions of the early 1 (E1), early 2 (E2b), and early 3 (E3) genes have been deleted. The unique deletions in this platform result in a dramatic decrease in late gene expression, leading to a marked reduction in host immune response to the vector. Ad5 [E1-, E2b-]-CEA vaccine (ETBX-011) has been employed in clinical studies as an active vaccine to induce immune responses to CEA in metastatic colorectal cancer patients. We report here the development of novel recombinant Ad5 [E1-, E2b-]-brachyury and-MUC1 vaccine constructs, each capable of activating antigen-specific human T cells in vitro and inducing antigen-specific CD4+ and CD8+ T cells in vaccinated mice. We also describe the use of a combination of the three vaccines (designated Tri-Ad5) of Ad5 [E1-, E2b-]-CEA, Ad5 [E1-, E2b-]-brachyury and Ad5 [E1-, E2b-]-MUC1, and demonstrate that there is minimal to no "antigenic competition" in in vitro studies of human dendritic cells, or in murine vaccination studies. The studies reported herein support the rationale for the application of Tri-Ad5 as a therapeutic modality to induce immune responses to a diverse range of human TAAs for potential clinical studies.


Subject(s)
Adenoviridae/genetics , Adenovirus Vaccines/therapeutic use , Antigens, Neoplasm/immunology , Cancer Vaccines/therapeutic use , Immunotherapy , Neoplasms/therapy , Adenovirus E1 Proteins/genetics , Adenovirus E1 Proteins/immunology , Adenovirus E2 Proteins/genetics , Adenovirus E2 Proteins/immunology , Animals , Antigens, Neoplasm/genetics , Carcinoembryonic Antigen/genetics , Carcinoembryonic Antigen/immunology , Dendritic Cells/immunology , Female , Flow Cytometry , Genetic Vectors/administration & dosage , Humans , Immunization , Interferon-gamma/metabolism , Mice , Mice, Inbred C57BL , Neoplasms/genetics , Neoplasms/immunology , Neoplasms/pathology , T-Lymphocytes/immunology , Tumor Cells, Cultured , Xenograft Model Antitumor Assays
2.
J Biosci ; 40(1): 79-90, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25740144

ABSTRACT

The use of adenovirus vector-based vaccines is a promising approach for generating antigen-specific immune responses. Improving vaccine potency is necessary in other approaches to address their inadequate protection for the majority of infectious diseases. This study is the first to reconstruct a recombinant replication-defective human adenovirus co-expressing E2 and invasin C-terminal (InvC) glycoproteins (rAd-E2-InvC). rAd-E2-InvC with 2 x 10(6) TCID50 was intramuscularly administered two times to CSFV-free pigs at 14 day intervals. No adverse clinical reactions were observed in any of the pigs after the vaccination. The CSFV E2-specific antibody titer was significantly higher in the rAd-E2-InvC group than that in the rAdV-E2 group as measured by NPLA and blocking ELISA. Pigs immunized with rAd-E2-InvC were completely protected against lethal challenge. Neither CSFV RNA nor pathological changes were detected in the tissues after CSFV challenge. These results demonstrate that rAd-E2-InvC could be an alternative to the existing CSF vaccine. Moreover, InvC that acts as an adjuvant could enhance the immunogenicity of rAdV-E2 and induce high CSFV E2-specific antibody titer and protection level.


Subject(s)
Adenovirus E2 Proteins/immunology , Adhesins, Bacterial/immunology , Classical Swine Fever/immunology , Viral Vaccines/immunology , Adenoviruses, Human/immunology , Adhesins, Bacterial/biosynthesis , Adhesins, Bacterial/genetics , Animals , Antibodies, Viral/immunology , Cell Line , Classical Swine Fever Virus/immunology , Glycoproteins/biosynthesis , Glycoproteins/immunology , HEK293 Cells , Humans , Random Allocation , Swine , Vaccination , Vaccine Potency , Viral Envelope Proteins/genetics , Viral Envelope Proteins/immunology , Virus Replication/genetics , Yersinia enterocolitica/immunology , Yersinia pseudotuberculosis/immunology
3.
Rev. argent. microbiol ; 47(1): 4-8, Mar. 2015. ilus, graf.
Article in English | LILACS, BINACIS | ID: biblio-1171812

ABSTRACT

Bovine viral diarrhea virus (BVDV) is an important cause of economic losses worldwide. E2 is an immunodominant protein and a promising candidate to develop subunit vaccines. To improve its immunogenicity, a truncated E2 (tE2) was fused to a single chain antibody named APCH, which targets to antigen-presenting cells. APCH-tE2 and tE2 proteins were expressed in the baculovirus system and their immunogenicity was firstly compared in guinea pigs. APCH-tE2 vaccine was the best one to evoke a humoral response, and for this reason, it was selected for a cattle vaccination experiment. All the bovines immunized with 1.5Ag of APCH-tE2 developed high levels of neutralizing antibodies against BVDV up to a year post-immunization, demonstrating its significant potential as a subunit vaccine. This novel vaccine is undergoing scale-up and was transferred to the private sector. Nowadays, it is being evaluated for registration as the first Argentinean subunit vaccine for cattle


El virus de la diarrea viral bovina (BVDV) es causante de importantes pérdidas económicas a nivel mundial. La proteína E2 es la inmunodominante del virus y es la candidata para desarrollar vacunas de subunidad. Para mejorar su inmunogenicidad, una versión truncada de la E2 (tE2) se fusionó a un anticuerpo de cadena simple (APCH), que se dirige a las células presentadoras de antígeno. Se expresaron las proteínas APCH-tE2 y tE2 en el sistema de baculovirus y su inmunogenicidad fue evaluada y comparada en cobayos; la proteína APCH-tE2 fue la que indujo la mejor respuesta humoral. Por dicha razón se la evaluó en bovinos utilizando 1,5µg de antígeno. Los animales presentaron altos títulos de anticuerpos neutralizantes contra BVDV hasta un año posinmunización. Esta nueva vacuna está en proceso de escalado y se transfirió al sector privado. Actualmente se está evaluando para su registro como la primera vacuna argentina de subunidad para bovinos


Subject(s)
Animals , Cattle , Guinea Pigs , Diarrhea Viruses, Bovine Viral/immunology , Vaccines, Subunit/biosynthesis , Antigen-Presenting Cells/drug effects , Baculoviridae/immunology , Immunization/veterinary , Adenovirus E2 Proteins/immunology , Diarrhea Viruses, Bovine Viral/drug effects , Antibodies, Neutralizing/analysis
4.
Yakugaku Zasshi ; 132(12): 1407-12, 2012.
Article in Japanese | MEDLINE | ID: mdl-23208048

ABSTRACT

Replication-incompetent adenovirus (Ad) vectors are widely used in gene therapy studies because they are beneficial as a gene delivery vehicle enabling high-titer production and highly efficient gene transfer into a wide spectrum of dividing and non-dividing cells in vitro and in vivo. Theoretically, Ad genes should not be expressed following transduction with a replication-incompetent Ad vector. However, leaky expression of viral genes is known to occur following transduction with a conventional Ad vector, which leads to a cellular immunity against Ad proteins as well as Ad protein-induced toxicity. Such Ad protein-induced cellular immunity and toxicity frequently cause both an elimination of Ad vector-transduced cells and tissue damage, leading to short-lived transgene expression. To date, no detailed analysis of the leaky expression profile of Ad genes has been performed. First, we systematically examined the expression profiles of Ad genes in cells using real-time RT-PCR following transduction with a conventional Ad vector. The results revealed that significant expression was found for E2A, E4, and pIX genes. Next, in order to suppress the leaky expression of Ad genes, complementary sequences for microRNA (miRNA) were inserted into the 3'-untranslated region of the E2A, E4, or pIX genes. miRNAs are an approximately 22-nt length non-coding RNA, and bind to imperfectly complementary sequences in the 3'-untranslated region of target mRNA, leading to suppression of gene expression via post-transcriptional regulation. Incorporation of the miRNA-targeted sequences significantly suppressed the leaky expression of Ad genes in an miRNA-dependent manner.


Subject(s)
Adenoviridae/genetics , Adenovirus E2 Proteins/genetics , Adenovirus E4 Proteins/genetics , Capsid Proteins/genetics , Gene Expression Regulation, Viral/drug effects , Gene Expression Regulation, Viral/genetics , Genes, Viral/genetics , Genetic Vectors/genetics , MicroRNAs/administration & dosage , MicroRNAs/pharmacology , 3' Untranslated Regions/genetics , Adenovirus E2 Proteins/immunology , Adenovirus E2 Proteins/toxicity , Adenovirus E4 Proteins/immunology , Adenovirus E4 Proteins/toxicity , Animals , Capsid Proteins/immunology , Capsid Proteins/toxicity , Gene Transfer Techniques , Genetic Therapy , Humans , Immunity, Cellular/immunology , MicroRNAs/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Viral/genetics , RNA, Viral/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Transcriptome , Transduction, Genetic , Transgenes
5.
J Immunol ; 188(8): 3791-803, 2012 Apr 15.
Article in English | MEDLINE | ID: mdl-22427636

ABSTRACT

During the process of B cell development, transcription factors, such as E2A and Ebf1, have been known to play key roles. Although transcription factors and chromatin regulators work in concert to direct the expression of B lineage-specific genes, little is known about the involvement of regulators for chromatin structure during B lymphopoiesis. In this article, we show that deletion of Srg3/mBaf155, a scaffold subunit of the SWI/SNF-like BAF complex, in the hematopoietic lineage caused defects at both the common lymphoid progenitor stage and the transition from pre-pro-B to early pro-B cells due to failures in the expression of B lineage-specific genes, such as Ebf1 and Il7ra, and their downstream target genes. Moreover, mice that were deficient in the expression of Brg1, a subunit of the complex with ATPase activity, also showed defects in early B cell development. We also found that the expression of Ebf1 and Il7ra is directly regulated by the SWI/SNF-like BAF complex. Thus, our results suggest that the SWI/SNF-like BAF complex facilitates early B cell development by regulating the expression of B lineage-specific genes.


Subject(s)
Cell Differentiation/immunology , Chromatin/immunology , Chromosomal Proteins, Non-Histone/immunology , Precursor Cells, B-Lymphoid/immunology , Transcription Factors/immunology , Adenovirus E2 Proteins/genetics , Adenovirus E2 Proteins/immunology , Animals , Basic Helix-Loop-Helix Transcription Factors/genetics , Basic Helix-Loop-Helix Transcription Factors/immunology , Cell Differentiation/genetics , Cell Lineage/immunology , Chromatin/genetics , Chromosomal Proteins, Non-Histone/deficiency , Chromosomal Proteins, Non-Histone/genetics , DNA Helicases/deficiency , DNA Helicases/genetics , DNA Helicases/immunology , Gene Expression Regulation , Mice , Mice, Knockout , Nuclear Proteins/deficiency , Nuclear Proteins/genetics , Nuclear Proteins/immunology , Poly I-C/pharmacology , Precursor Cells, B-Lymphoid/cytology , Receptors, Interleukin-7/genetics , Receptors, Interleukin-7/immunology , Signal Transduction , Trans-Activators/genetics , Trans-Activators/immunology , Transcription Factors/deficiency , Transcription Factors/genetics
6.
Cancer Res ; 70(19): 7431-41, 2010 Oct 01.
Article in English | MEDLINE | ID: mdl-20823150

ABSTRACT

Cancer vaccines may have applications in the therapy and prevention of mammary carcinoma. To investigate such applications, we constructed a recombinant adenoviral vaccine expressing a kinase-inactive mutant form of human HER2 and introduced this into BALB/c wild-type (WT) or HER2 transgenic mice. Here, we report contributions by antibody responses and natural killer (NK) cells in tumor protection in this model. One i.p. vaccination protected WT mice from the HER2-expressing mouse carcinoma D2F2/E2. Half of the HER2 transgenic mice were protected fully and long term after preventive vaccination. Tumor growth in mice that eventually developed neoplastic lesions was delayed. Protection in WT and HER2 transgenic mice was associated with high or low levels of IgG2a antibodies, respectively, whereas CTLs were observed in WT but not in HER2 transgenic mice. Depleting CD4(+) or CD8(+) cells in vaccinated WT mice had limited effects, suggesting that protection was largely independent of CD4(+) or CD8(+) T cells. In contrast, antibody-mediated tumor rejection seemed to contribute significantly based on a loss of protection in mice deficient for Fc-γ RI/III or B cells. Further, a role for antibody-dependent cellular cytotoxicity (ADCC) mediated by NK cells was indicated by evidence that vaccine protection could be abolished by in vivo depletion of NK cells. Lastly, NK cells and immune sera purified from WT or HER2 transgenic mice exhibited efficient ADCC of HER2-expressing tumor cells in vitro. Our findings define a critical requirement for NK cells in vaccine-induced protection against HER2-expressing tumors.


Subject(s)
Cancer Vaccines/immunology , Killer Cells, Natural/immunology , Mammary Neoplasms, Experimental/immunology , Receptor, ErbB-2/immunology , Adenoviridae/genetics , Adenoviridae/immunology , Adenovirus E2 Proteins/genetics , Adenovirus E2 Proteins/immunology , Animals , Antibody Specificity , Antibody-Dependent Cell Cytotoxicity/immunology , Cancer Vaccines/genetics , Cell Line, Tumor , Humans , Immunoglobulin G/immunology , Mammary Neoplasms, Experimental/prevention & control , Mice , Mice, Inbred BALB C , Mice, Knockout , Mice, Transgenic , Receptor, ErbB-2/genetics , Receptors, Fc/immunology , T-Lymphocytes/immunology , Vaccines, Inactivated/genetics , Vaccines, Inactivated/immunology
7.
Sheng Wu Gong Cheng Xue Bao ; 25(5): 679-85, 2009 May.
Article in Chinese | MEDLINE | ID: mdl-19670635

ABSTRACT

We have previously evaluated a Semliki Forest virus (SFV) replicon vectored DNA vaccine (pSFV1CS2-E2) and a recombinant adenovirus (rAdV-E2) expressing the E2 glycoprotein of classical swine fever virus (CSFV) in pigs. The results showed that the immunized pigs were protected from virulent challenge, but few pigs showed short-term fever and occasional pathological changes following virulent challenge. To enhance the immunogenecity of the vaccines, we tried a prime-boost vaccination strategy using a combination of prime with pSFV1CS2-E2 followed by boost with rAdV-E2. The results showed that all the immunized pigs developed high-level CSFV-specific antibodies following prime-boost immunization. When challenged with virulent CSFV, the immunized pigs (n = 5) from the heterologous boost group showed no clinical symptoms, and CSFV RNA was not detected following challenge, whereas one of five pigs from the homologous boost group developed short-term fever and CSFV RNA was detected. This demonstrates that the heterologous prime-boost vaccination regime has the potential to prevent against virulent challenge.


Subject(s)
Adenoviridae/genetics , Classical Swine Fever Virus/immunology , Classical Swine Fever/prevention & control , Semliki forest virus/genetics , Vaccines, DNA/immunology , Viral Vaccines/immunology , Adenoviridae/metabolism , Adenovirus E2 Proteins/genetics , Adenovirus E2 Proteins/immunology , Animals , Classical Swine Fever/immunology , Classical Swine Fever Virus/genetics , Genetic Vectors , Immunization, Secondary , Replicon/genetics , Semliki forest virus/metabolism , Swine , Viral Envelope Proteins/genetics , Viral Envelope Proteins/metabolism
8.
Cancer Gene Ther ; 16(9): 673-82, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19229288

ABSTRACT

Recombinant serotype 5 adenovirus (Ad5) vectors lacking E1 expression induce robust immune responses against encoded transgenes in pre-clinical models, but have muted responses in human trials because of widespread pre-existing anti-adenovirus immunity. Attempts to circumvent Ad5-specific immunity by using alternative serotypes or modifying capsid components have not yielded profound clinical improvement. To address this issue, we explored a novel alternative strategy, specifically reducing the expression of structural Ad5 genes by creating E1 and E2b deleted recombinant Ad5 vectors. Our data show that [E1-, E2b-]vectors retaining the Ad5 serotype are potent immunogens in pre-clinical models despite the presence of significant Ad5-specific immunity, in contrast to [E1-] vectors. These pre-clinical studies with E1 and E2b-deleted recombinant Ad5 vectors suggest that anti-Ad immunity will no longer be a limiting factor, and that clinical trials to evaluate their performance are warranted.


Subject(s)
Adenoviridae/genetics , Adenoviridae/immunology , Adenovirus E1 Proteins/genetics , Adenovirus E2 Proteins/genetics , Adenovirus E3 Proteins/genetics , Cancer Vaccines/immunology , Genetic Vectors/immunology , Adenovirus E1 Proteins/immunology , Adenovirus E2 Proteins/immunology , Adenovirus E3 Proteins/immunology , Animals , Antigen Presentation , Cancer Vaccines/genetics , Carcinoembryonic Antigen/metabolism , Cell Differentiation , Cells, Cultured , Cytotoxicity, Immunologic , Dendritic Cells/cytology , Dendritic Cells/immunology , Dendritic Cells/metabolism , Gene Deletion , Humans , Killer Cells, Natural/immunology , Kinetics , Mice , Mice, Inbred C57BL
9.
Arch Virol ; 153(8): 1593-8, 2008.
Article in English | MEDLINE | ID: mdl-18607674

ABSTRACT

The sequence TAVSPTTLR is a conserved and linear neutralizing epitope on the glycoprotein E2 of classical swine fever virus. In this study, TAVSPTTLR-directed antibodies, induced either by virions or by an epitope-focused immunogen, were characterized. The results revealed that despite the same epitope specificity, the antibodies induced by different immunogens varied significantly both in the neutralizing test and in binding inhibition assays. This suggests that the protective immunity induced by this epitope is due to more than simply the epitope specificity and that this epitope might need essential contributions from its flanking context to induce functional epitope-specific antibodies.


Subject(s)
Adenovirus E2 Proteins/immunology , Antibodies, Viral/immunology , Antibody Formation , Classical Swine Fever Virus/immunology , Classical Swine Fever/immunology , Epitopes/chemistry , Adenovirus E2 Proteins/genetics , Animals , Antibodies, Viral/genetics , Antibody Formation/immunology , Antibody Specificity , Classical Swine Fever/virology , Classical Swine Fever Virus/genetics , Epitopes/genetics , Epitopes/immunology , Swine
10.
J Med Virol ; 66(2): 258-62, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11782937

ABSTRACT

The association of the newly identified viruses, GB virus C (GBV-C) and TT virus (TTV), with autoimmune hepatitis remains to be elucidated. Sera from 20 Japanese patients with autoimmune hepatitis and 50 volunteer blood donors were assayed for GBV-C RNA, antibodies to the GBV-C second envelope protein (E2), and TTV DNA. GBV-C RNA was examined by reverse-transcription polymerase chain reaction (PCR). Anti-GBV-C E2 (a marker of past infection) was tested by an enzyme-linked immunosorbent assay. TTV DNA was amplified by PCR using two different sets of primers: one derived from the original N22 sequence (Set A) and the other from the untranslated region (Set B). None of the patients or controls had GBV-C RNA. Anti-GBV-C E2 was found significantly more often in patients with autoimmune hepatitis (3/20) than in controls (1/50; P = 0.034). The prevalence of TTV DNA detected by primers Set A and that detected with either Set A or B were similar among patients with autoimmune hepatitis (4/20 and 16/20, respectively) and controls (9/50 and 40/50, respectively). Clinical characteristics did not differ in association with any of these viral markers. Of the 13 TTV isolates amplified with Set A, seven were classified as genotype 1a, four as genotype 1b, and 2 as genotype 3; no particular strain was associated with autoimmune hepatitis. These findings provide no compelling evidence that GBV-C or TTV has a pathogenic role in autoimmune hepatitis.


Subject(s)
DNA Virus Infections/complications , Flaviviridae Infections/complications , Flaviviridae/pathogenicity , Hepatitis, Autoimmune/virology , Hepatitis, Viral, Human/complications , Torque teno virus/pathogenicity , Adenovirus E2 Proteins/immunology , Adult , Aged , Blood Donors , DNA Virus Infections/virology , DNA, Viral/analysis , Female , Flaviviridae Infections/virology , Hepatitis Antibodies/blood , Hepatitis, Viral, Human/virology , Humans , Japan , Male , Middle Aged , RNA, Viral/blood
11.
Infection ; 29(4): 219-21, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11545484

ABSTRACT

BACKGROUND: The aim was to estimate the prevalence and the persistence of GB virus C/hepatitis G virus (GBV-C/HGV) exposure markers in a group at high risk for transfusion-transmitted agents. PATIENTS AND METHODS: Serum samples from 37 thalassemic patients were screened for GBV-C/HGV RNA by reverse transcription PCR (RT-PCR) and for antibodies to the envelope protein E2 of GBV-C/HGV (anti-E2). RESULTS AND DISCUSSION: GBV-C/HGV RNA and anti-E2 were detected in 13 (35%) and 12 (32%) sera, respectively. Contemporary presence of both markers was found in one patient. GBV-C/HGV exposure was found in 24 patients (64.8%). Mean levels of liver enzymes were similar in both exposed and unexposed GBV-C/HGV groups. 33 out of 35 patients showed no change in GBV-C/HGV RNA and anti-E2 status in sera taken 6 months apart. The rate of persistent infection was 92.3% and the anti-E2 seroconversion rate was 23% for sera taken at least 6 months apart. The temporal overlap between anti-E2 seroconversion and loss of detectable GBV-C/HGV RNA may last more than 6 months.


Subject(s)
Flaviviridae Infections/etiology , GB virus C/isolation & purification , Hepatitis, Viral, Human/etiology , Thalassemia/therapy , Transfusion Reaction , Adenovirus E2 Proteins/immunology , Adolescent , Adult , Biomarkers/blood , Child , Female , Flaviviridae Infections/diagnosis , GB virus C/genetics , GB virus C/immunology , Hepatitis Antibodies/isolation & purification , Hepatitis, Viral, Human/diagnosis , Humans , Italy , Male , RNA, Viral/isolation & purification , Reverse Transcriptase Polymerase Chain Reaction , Risk Factors
12.
Intervirology ; 44(6): 350-4, 2001.
Article in English | MEDLINE | ID: mdl-11805441

ABSTRACT

To identify and characterize the protein encoded by the E2A region of porcine adenovirus (PAV)-3, DNA sequence coding for a portion (amino acids 102-457) of the DNA binding protein (DBP) open reaching frame was cloned and expressed in Escherichia coli as a fusion protein with glutathione S-transferase protein of Schistosoma japonica. The affinity-purified fusion protein was used to immunize rabbits. Immunoprecipitation/Western blot analysis demonstrated that the antisera specifically recognized a protein of 50 kD in PAV-3-infected cells. Immunoperoxidase staining detected the DBP protein predominantly in the nucleus of the cells. Western blot analysis demonstrated that DBP was detected as early as 6 h after infection and remained detectable throughout the infection. Based on these results, a novel assay for quantitation of PAV-3 was established. The assay is less time consuming and can be performed in different porcine cells. In addition, virus titers determined by this assay are comparable to the standard plaque assay.


Subject(s)
Adenovirus E2 Proteins/metabolism , Adenoviruses, Porcine/metabolism , Adenovirus E2 Proteins/biosynthesis , Adenovirus E2 Proteins/genetics , Adenovirus E2 Proteins/immunology , Adenoviruses, Porcine/genetics , Adenoviruses, Porcine/isolation & purification , Animals , Antibodies, Viral/biosynthesis , Cell Line, Transformed , Glutathione Transferase/genetics , Rabbits , Recombinant Fusion Proteins/genetics , Swine , Viral Plaque Assay
13.
J Virol ; 74(24): 11598-607, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11090158

ABSTRACT

We describe an improved genetic immunization strategy for eliciting a full spectrum of anti-hepatitis C virus (HCV) envelope 2 (E2) glycoprotein responses in mammals through electrical gene transfer (EGT) of plasmid DNA into muscle fibers. Intramuscular injection of a plasmid encoding a cross-reactive hypervariable region 1 (HVR1) peptide mimic fused at the N terminus of the E2 ectodomain, followed by electrical stimulation treatment in the form of high-frequency, low-voltage electric pulses, induced more than 10-fold-higher expression levels in the transfected mouse tissue. As a result of this substantial increment of in vivo antigen production, the humoral response induced in mice, rats, and rabbits ranged from 10- to 30-fold higher than that induced by conventional naked DNA immunization. Consequently, immune sera from EGT-treated mice displayed a broader cross-reactivity against HVR1 variants from natural isolates than sera from injected animals that were not subjected to electrical stimulation. Cellular response against E2 epitopes specific for helper and cytotoxic T cells was significantly improved by EGT. The EGT-mediated enhancement of humoral and cellular immunity is antigen independent, since comparable increases in antibody response against ciliary neurotrophic factor or in specific anti-human immunodeficiency virus type 1 gag CD8(+) T cells were obtained in rats and mice. Thus, the method described potentially provides a safe, low-cost treatment that may be scaled up to humans and may hold the key for future development of prophylactic or therapeutic vaccines against HCV and other infectious diseases.


Subject(s)
Adenovirus E2 Proteins/immunology , DNA, Viral/immunology , Hepacivirus/immunology , Hepatitis C/immunology , Viral Hepatitis Vaccines/immunology , Adenovirus E2 Proteins/genetics , Animals , B-Lymphocytes/immunology , B-Lymphocytes/virology , DNA, Viral/genetics , Electroporation , Hepatitis C/prevention & control , Immunity , Mice , Rabbits , Rats , T-Lymphocytes/immunology , T-Lymphocytes/virology , Transfection , Vaccines, DNA/immunology
14.
J Virol ; 74(24): 11619-25, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11090160

ABSTRACT

The major structural glycoprotein E2 of classical swine fever virus (CSFV) is responsible for eliciting neutralizing antibodies and conferring protective immunity. The current structural model of this protein predicts its surface-exposed region at the N terminus with a short stretch of the C-terminal residues spanning the membrane envelope. In this study, the N-terminal region of 221 amino acids (aa) covering aa 690 to 910 of the CSFV strain Alfort/187 E2, expressed as a fusion product in Escherichia coli, was shown to contain the epitope recognized by a monoclonal antibody (WH303) with affinity for various CSFV strains but not for the other members of the Pestivirus genus, bovine viral diarrhea virus (BVDV) and border disease virus (BDV). This region also contains the sites recognized by polyclonal immunoglobulin G (IgG) antibodies of a pig hyperimmune serum. Serial deletions of this region precisely defined the epitope recognized by WH303 to be TAVSPTTLR (aa 829 to 837) of E2. Comparison of the sequences around the WH303-binding site among the E2 proteins of pestiviruses indicated that the sequence TAVSPTTLR is strongly conserved in CSFV strains but highly divergent among BVDV and BDV strains. These results provided a structural basis for the reactivity patterns of WH303 and also useful information for the design of a peptide containing this epitope for potential use in the detection and identification of CSFV. By deletion analysis, an antigenic domain capable of reacting with pig polyclonal IgG was found 17 aa from the WH303 epitope within the N-terminal 123 residues (aa 690 to 812). Small N- or C-terminal deletions introduced into the domain disrupt its reactivity with pig polyclonal IgG, suggesting that this is the minimal antigenic domain required for binding to pig antibodies. This domain could have eliminated or reduced the cross-reactivity with other pestiviruses and may thus have an application for the serological detection of CSFV infection; evaluation of this is now possible, since the domain has been expressed in E. coli in large amounts and purified to homogeneity by chromatographic methods.


Subject(s)
Adenovirus E2 Proteins/immunology , Antigens, Viral/immunology , Classical Swine Fever Virus/immunology , Immunoglobulin G/immunology , Adenovirus E2 Proteins/genetics , Amino Acid Sequence , Animals , Antibodies, Monoclonal/immunology , Antibodies, Viral/genetics , Antibodies, Viral/immunology , Antigen-Antibody Reactions/genetics , Antigens, Viral/genetics , Base Sequence , Cattle , Classical Swine Fever Virus/genetics , Epitope Mapping , Epitopes/genetics , Epitopes/immunology , Gene Deletion , Molecular Sequence Data , Swine
15.
Eur J Clin Microbiol Infect Dis ; 19(9): 721-4, 2000 Sep.
Article in English | MEDLINE | ID: mdl-11057510

ABSTRACT

The prevalence of GB virus C (GBV-C)/ hepatitis G virus (HGV) RNA and antibodies to the structural E2 protein was investigated in a cohort of HIV-1 infected patients. Of 346 individuals, RNA was detected in 143 and E2 antibodies were detected in 73, for an overall prevalence of 62.4%. Intravenous drug use and homosexuality were identified as major transmission risk factors. GBV-C/HGV RNA prevalence was associated with hepatitis B coinfection, whereas antibodies to E2 were associated with older age and lower CD4+ cell counts. GBV-C/HGV infection was frequent in this group of HIV-infected patients and was associated with older age, lower CD4 + cell counts, and the presence of hepatitis B surface antigen.


Subject(s)
Flaviviridae/isolation & purification , HIV Infections/complications , Hepatitis Antibodies/blood , Hepatitis, Viral, Human/epidemiology , RNA, Viral/blood , Adenovirus E2 Proteins/immunology , Adult , Female , Flaviviridae/genetics , Flaviviridae/immunology , Hepatitis Antibodies/immunology , Hepatitis, Viral, Human/complications , Hepatitis, Viral, Human/virology , Humans , Male , Middle Aged , Prevalence
16.
J Pediatr ; 133(3): 382-5, 1998 Sep.
Article in English | MEDLINE | ID: mdl-9738721

ABSTRACT

OBJECTIVES: To study viral persistence and antibody responses after hepatitis G virus (HGV) infection in children of various ages. STUDY DESIGN: We performed an enzyme immunoassay for antibodies to E2 protein (anti-E2) of HGV and reverse-transcription polymerase chain reaction assay for HGV RNA on serum samples. RESULTS: Of 28 infants born to HGV RNA-positive mothers, 17 were found to be positive for HGV RNA. None were positive for anti-E2. All 17 infected infants continued to have viremia except 1 who converted to HGV RNA-negative status at 24 months. Six infants had mild elevations of alanine aminotransferase levels (5 HGV-positive and 1 HGV-negative). An additional 14 HGV-infected children (aged 6 months to 14 years) with posttransfusion HGV infection were tested for anti-E2 3 months and 12 months after blood transfusion. None of the HGV RNA-positive serum samples were positive for anti-E2; however, 4 of the 8 children with resolving HGV infection were positive for anti-E2 1 year later. CONCLUSIONS: Mother-to-infant transmission of HGV resulted in a high viral persistence rate and lack of immune responses to HGV. In contrast, anti-E2 appeared in children who recovered from posttransfusion HGV infection. Mode of transmission and age at infection may be important factors in determining persistent HGV infection and defective immune response to HGV.


Subject(s)
Adenovirus E2 Proteins/immunology , Flaviviridae/immunology , Hepatitis Antibodies/immunology , Hepatitis, Viral, Human/immunology , Adolescent , Age Factors , Alanine Transaminase/blood , Blood Transfusion , Child , Child, Preschool , Enzyme-Linked Immunosorbent Assay , Female , Flaviviridae/genetics , Follow-Up Studies , Hepatitis, Viral, Human/enzymology , Hepatitis, Viral, Human/transmission , Humans , Infant , Infectious Disease Transmission, Vertical , Male , Polymerase Chain Reaction , RNA, Viral/analysis , Viremia/virology
17.
J Virol ; 72(3): 2022-32, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9499056

ABSTRACT

Isogenic, E3-deleted adenovirus vectors defective in E1, E1 and E2A, or E1 and E4 were generated in complementation cell lines expressing E1, E1 and E2A, or E1 and E4 and characterized in vitro and in vivo. In the absence of complementation, deletion of both E1 and E2A completely abolished expression of early and late viral genes, while deletion of E1 and E4 impaired expression of viral genes, although at a lower level than the E1/E2A deletion. The in vivo persistence of these three types of vectors was monitored in selected strains of mice with viral genomes devoid of transgenes to exclude any interference by immunogenic transgene-encoded products. Our studies showed no significant differences among the vectors in the short-term maintenance and long-term (4-month) persistence of viral DNA in liver and lung cells of immunocompetent and immunodeficient mice. Furthermore, all vectors induced similar antibody responses and comparable levels of adenovirus-specific cytotoxic T lymphocytes. These results suggest that in the absence of transgenes, the progressive deletion of the adenovirus genome does not extend the in vivo persistence of the transduced cells and does not reduce the antivirus immune response. In addition, our data confirm that, in the absence of transgene expression, mouse cellular immunity to viral antigens plays a minor role in the progressive elimination of the virus genome.


Subject(s)
Adenovirus E1 Proteins/genetics , Adenovirus E2 Proteins/genetics , Adenovirus E4 Proteins/genetics , Adenoviruses, Human , Capsid Proteins , Gene Deletion , Genetic Vectors , Adenovirus E1 Proteins/biosynthesis , Adenovirus E1 Proteins/immunology , Adenovirus E2 Proteins/biosynthesis , Adenovirus E2 Proteins/immunology , Adenovirus E4 Proteins/immunology , Adenoviruses, Human/genetics , Adenoviruses, Human/immunology , Adenoviruses, Human/metabolism , Animals , Capsid/biosynthesis , Cell Line , DNA-Binding Proteins/biosynthesis , Female , Genetic Vectors/genetics , Genetic Vectors/immunology , Genetic Vectors/metabolism , Genome, Viral , Humans , Mice , Mice, Inbred CBA , Mice, SCID , Time Factors , Virus Latency
19.
Blood ; 90(9): 3776-80, 1997 Nov 01.
Article in English | MEDLINE | ID: mdl-9345065

ABSTRACT

The aims of this study were to determine the outcome and the natural history of GBV-C/hepatitis G virus (HGV) infection and to establish the frequency of acute or persistent infections in multiply-transfused individuals and blood donors. We used a GBV-C/HGV RNA polymerase chain reaction (PCR) and an assay evidencing antibodies to the envelop protein E2, which is considered a marker for virus clearance. Among 16 PCR-positive recipients, 11 were still positive for GBV-C/HGV RNA at the end of the study period; six of the 16 recipients were GBV-C/HGV infected during the study period and thus had a well-defined date of infection. The 16 patients were shown to carry GBV-C/HGV RNA over a mean period of 4.4 years, for a mean observational period (defined as the follow-up period since the first sample positive for GBV-C/HGV RNA) of 5.3 years. Within the limits of the study period, the patients with a well-defined date of infection were positive for GBV-C/HGV RNA during a mean period of 4.7 years. If defined by the presence of GBV-C/HGV RNA for at least 6 months, the persistent infection rate was 100% in this recipient cohort. Serum anti-E2 antibody was evidenced at least once in five (31.2%) recipients and, except in one case, became detectable after the loss of GBV-C/HGV RNA. Among the 11 blood donors, all were still positive for GBV-C/HGV RNA after a mean follow-up period of 7.7 months. The persistent infection rate was 100% in this donor cohort. Once acquired, the infection to GBV-C/HGV generally tends to persist in immunocompetent patients.


Subject(s)
Blood Donors , Flaviviridae , Hepatitis, Viral, Human/transmission , Transfusion Reaction , Adenovirus E2 Proteins/immunology , Antigens, Viral/immunology , Cohort Studies , Flaviviridae/genetics , Flaviviridae/isolation & purification , Follow-Up Studies , Humans , Polymerase Chain Reaction , RNA, Viral/analysis , Serology
20.
J Med Virol ; 53(4): 348-53, 1997 Dec.
Article in English | MEDLINE | ID: mdl-9407382

ABSTRACT

Although infection with GB virus-C/hepatitis G virus (GBV-C/HGV) by blood transfusion is well documented, little is known about the other routes of transmission. The prevalence of GBV-C/HGV infection in spouses of index patients and the related risk factors were studied. Hepatitis C virus (HCV) and GBV-C/HGV infections were studied in spouses of 100 patients with hepatitis C, of whom 12 were found to be also positive for GBV-C/HGV RNA. For couples both with GBV-C/ HGV viremia, nucleotide sequences of the divergent envelope region were analyzed by phylogenetic tree constructions. For HCV infection, anti-HCV was found in 14 (14%) of the 100 spouses. Five spouses (42%) of the 12 patients with dual infection of GBV-C/HGV and HCV had evidence of GBV-C/HGV infection, three had viral RNA, and two had antibodies to a recombinant HGV envelope protein E2. Nucleotide sequence comparison and phylogenetic tree analysis of the genome in the GBV-C/HGV infected couple revealed the isolates to be closely related. These results suggest that spouses of patients with GBV-C/HGV infection are at a higher risk of acquiring GBV-C/HGV as compared with HCV, and they should be educated to avoid GBV-C/HGV infection from their spouses, in case GBV-C/HGV is shown to be pathogenic.


Subject(s)
Disease Transmission, Infectious , Flaviviridae/genetics , Hepatitis, Viral, Human/transmission , Spouses , Adenovirus E2 Proteins/genetics , Adenovirus E2 Proteins/immunology , Adult , Aged , Base Sequence , Female , Flaviviridae/chemistry , Flaviviridae/classification , Hepacivirus/genetics , Hepacivirus/immunology , Hepatitis C/complications , Hepatitis C/transmission , Hepatitis C/virology , Hepatitis, Viral, Human/complications , Hepatitis, Viral, Human/virology , Humans , Male , Middle Aged , Molecular Sequence Data , Phylogeny , RNA, Viral/blood , Sequence Homology, Nucleic Acid , Viremia
SELECTION OF CITATIONS
SEARCH DETAIL
...